Symmetrel (Amantadine Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 26, 2017 Category: Drugs & Pharmacology Source Type: news
Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 6, 2017 Category: Drugs & Pharmacology Source Type: news
Acute hallucinosis related to amantadine use in the setting of traumatic brain injury: a case report - Schoen B, Eickmeyer S.
[Abstract unavailable]
Language: en... (Source: SafetyLit)
Source: SafetyLit - October 1, 2016 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Adjunctive amantadine treatment for aggressive behavior in children: a series of eight cases - McGrane IR, Loveland JG, Zaluski HJ.
We describe our experience with adjunctive amantadine treatment for... (Source: SafetyLit)
Source: SafetyLit - August 4, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news
Long-Acting Drug Safe in Dyskinesia (CME/CE)
(MedPage Today) -- Extended-release amantadine well tolerated over 41 weeks (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 23, 2016 Category: Geriatrics Source Type: news
Extended-Release Amantadine May Improve Levodopa Dyskinesia Control
VANCOUVER — An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. (Source: Caring for the Ages)
Source: Caring for the Ages - May 28, 2016 Category: Health Management Authors: M. Alexander Otto Source Type: news
Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine... (Source: Family Practice News)
Source: Family Practice News - April 21, 2016 Category: Primary Care Source Type: news
Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 21, 2016 Category: Neurology Source Type: news
Amantadine (Symmetrel, Lysovir) may be out of stock due to manufacturing delays
Anyone currently taking amantadine, sometimes prescribed for fatigue in MS, may want to check with their pharmacist to ensure there will be stocks ready for their next prescription. (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 28, 2014 Category: Neurology Source Type: news
Adamas starts Phase III trial of ADS-5102 to treat PD patients with levodopa-induced dyskinesia
US-based Adamas Pharmaceuticals has started a pivotal Phase III clinical trial of its most advanced wholly owned product candidate ADS-5102 (amantadine HCl) for the treatment of patients with Parkinson's disease (PD) who have developed movement disor… (Source: Drug Development Technology)
Source: Drug Development Technology - June 10, 2014 Category: Pharmaceuticals Source Type: news
Amantadine Has Lasting Benefit on Levodopa-Induced DyskinesiaAmantadine Has Lasting Benefit on Levodopa-Induced Dyskinesia
A large study shows a 'clinically important' and long-lasting antidyskinetic effect of amantadine in Parkinson's patients receiving levodopa. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 8, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Featured in NEJM Journal Watch: Amantadine for Irritability After Traumatic Brain Injury (FREE)
By the NEJM Journal Watch Editors
It's a first-line option, according … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 24, 2013 Category: Primary Care Source Type: news
New Sleep Articles from October
It was another busy month with plenty of new information available about sleep disorders. Review some of the new sleep articles available from October. Discover surprising signs of obstructive sleep apnea and insomnia, as well as indications that your continuous positive airway pressure (CPAP) is not working properly. Expand your vocabulary by learning about three important neurotransmitters: GABA, norepinephrine, and epinephrine. Consider some reasons why you may wish to avoid using sleeping pills altogether. Finally, learn about the use of the prescription medication amantadine to treat fatigue in multiple sclerosis.
Re...
Source: About Sleep Disorders - October 30, 2013 Category: Sleep Medicine Source Type: news
Nanosecond Dynamics of InfluenzaA/M2TM and an Amantadine Resistant Mutant Probed by Time-Dependent Red Shifts of a Native Tryptophan.
Abstract
Proteins involved in functions such as electron transfer or ion transport must be capable of stabilizing transient charged species on time scales ranging from picoseconds to microseconds. We study the influenza A M2 proton channel, containing a tryptophan residue that serves as an essential part of the proton conduction pathway. We induce a transition dipole in tryptophan by photoexcitation, and then probe the dielectric stabilization of its excited state. The magnitude of the stabilization over this time regime was larger than that generally found for tryptophan in membrane or protein environment...
Source: Chemical Physics - August 30, 2013 Category: Chemistry Authors: Nanda V, Cristian L, Toptygin D, Brand L, Degrado WF Tags: Chem Phys Source Type: news
Amantadine ER Curbs Levodopa-Induced Dyskinesia in PDAmantadine ER Curbs Levodopa-Induced Dyskinesia in PD
An investigational extended-release formulation of amantadine with a unique chronotherapeutic pharmacokinetic profile eases levodopa-induced dyskinesia in a phase 2/3 study. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
